WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for VRTX

Based on 16 analysts offering 12 month price targets for Vertex Pharmaceuticals Inc.
Min Forecast
$364.00-8.47%
Avg Forecast
$451.75+13.59%
Max Forecast
$559.00+40.56%

Should I buy or sell VRTX stock?

Based on 16 analysts offering ratings for Vertex Pharmaceuticals Inc.
Buy
Strong Buy
8 analysts 50%
Buy
4 analysts 25%
Hold
3 analysts 18.75%
Sell
0 analysts 0%
Strong Sell
1 analysts 6.25%

Be the first to know when Wall Street analysts revise their VRTX stock forecasts and price targets.

VRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-18
lockedlocked$00.00+00.00%2024-04-17
lockedlocked$00.00+00.00%2024-04-15
lockedlocked$00.00+00.00%2024-04-12
lockedlocked$00.00+00.00%2024-04-11
Evercore ISI Group
Top 16%
85
BuyUpgrades$438.00+10.13%2024-04-11
Cantor Fitzgerald
Bottom 14%
14
Strong BuyReiterates$440.00+10.64%2024-02-20
JP Morgan
Top 12%
89
Strong BuyMaintains$450.00+13.15%2024-02-06
Wells Fargo
Top 9%
92
Strong BuyMaintains$540.00+35.78%2024-02-06
RBC Capital
Top 5%
96
HoldMaintains$420.00+5.61%2024-02-06

1 of 2

Forecast return on equity

Is VRTX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is VRTX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VRTX revenue forecast

What is VRTX's revenue in the next 3 years based on estimates from 12 analysts?
Avg 1 year Forecast
$10.7B+8.29%
Avg 2 year Forecast
$11.7B+18.41%
Avg 3 year Forecast
$12.8B+29.44%
VRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRTX earnings growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
2.45%
Industry
7.17%
Market
21.46%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

VRTX revenue growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
8.93%
Industry
37.04%
Market
9.92%
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRTX$397.70$451.75+13.59%Buy
REGN$890.68$1,004.50+12.78%Buy
MRNA$106.18$127.14+19.74%Buy
ARGX$368.60$511.67+38.81%Strong Buy
BNTX$86.71$114.71+32.30%Hold
View Top Biotech Stocks

Vertex Pharmaceuticals Stock Forecast FAQ

Is Vertex Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: VRTX) stock is to Buy VRTX stock.

Out of 16 analysts, 8 (50%) are recommending VRTX as a Strong Buy, 4 (25%) are recommending VRTX as a Buy, 3 (18.75%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 1 (6.25%) are recommending VRTX as a Strong Sell.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What is VRTX's revenue growth forecast for 2024-2026?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Vertex Pharmaceuticals's revenue in 2024 is $9,869,200,000.On average, 12 Wall Street analysts forecast VRTX's revenue for 2024 to be $2,760,654,451,187, with the lowest VRTX revenue forecast at $2,739,612,696,496, and the highest VRTX revenue forecast at $2,780,846,373,164. On average, 12 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,018,592,112,087, with the lowest VRTX revenue forecast at $2,861,577,897,977, and the highest VRTX revenue forecast at $3,387,810,329,966.

In 2026, VRTX is forecast to generate $3,299,766,627,498 in revenue, with the lowest revenue forecast at $3,026,236,215,286 and the highest revenue forecast at $3,742,105,330,392.

What is VRTX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VRTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VRTX's Price Target?

According to 16 Wall Street analysts that have issued a 1 year VRTX price target, the average VRTX price target is $451.75, with the highest VRTX stock price forecast at $559.00 and the lowest VRTX stock price forecast at $364.00.

On average, Wall Street analysts predict that Vertex Pharmaceuticals's share price could reach $451.75 by Apr 18, 2025. The average Vertex Pharmaceuticals stock price prediction forecasts a potential upside of 13.59% from the current VRTX share price of $397.70.

What is VRTX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VRTX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.